Polymorphism L26V in the cathepsin B gene may be associated with a risk of prostate cancer and differentiation

Journal of International Medical Research

Volumn 37, Issue 5, 2009, Pages 1604-1610

  Stiblar Martincic D ^a   Hajdinjak, Tine ^b  

^a UNIVERSITY OF MARIBOR   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

Author keywords

Cysteine endopeptidases; Genetic disease predisposition; Prostate adenocarcinoma (PCa); Single nuceotide polymorphism

Indexed keywords

CATHEPSIN B; LEUCINE; VALINE;

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; GLEASON SCORE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE ADENOCARCINOMA; SINGLE NUCLEOTIDE POLYMORPHISM; SLOVENIA; TUMOR DIFFERENTIATION;

EID: 70449686397     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000903700539     Document Type: Article

References (31)

1. Bahnson RR: Improving prostate cancer detection. J Urol 2000; 164: 405.
2. Ferlay JB, Pisani P, Parkin DM: Cancer Incidence, Mortality and Prevalence Worldwide. Lyon: IARC Press, 2001.
3. Catalona WJ, Han M: Definitive therapy for localized prostate cancer - an overview. In: Campbell-Walsh Urology, 9th edn (Wein AJ, Kavoussi LR, Novick AC, et al, eds). Philadelphia: Saunders, 2007; pp 2932 - 2933.
4. Steinberg GD, Carter BS, Beaty TH, et al: Family history and the risk of prostate cancer. Prostate 1990; 17: 337-347.
5. Gronberg H, Damber L, Damber JE: Familial prostate cancer in Sweden. A nationwide register cohort study. Cancer 1996; 77: 138-143. (Pubitemid 26002749)
6. Cudic M, Fields GB: Extracellular proteases as targets for drug development. Curr Protein Pept Sci 2009; 10: 297-307.
7. Roshy S, Sloane BF, Moin K: Pericellular cathepsin B and malignant progression. Cancer Metastasis Rev 2003; 22: 271-286.
8. Sinha AA, Wilson MJ, Gleason DF, et al: Immunohistochemical localization of cathepsin B in neoplastic human prostate. Prostate 1995; 26: 171-178.
9. Sinha AA, Jamuar MP, Wilson MJ, et al: Plasma membrane association of cathepsin B in human prostate cancer: biochemical and immunogold electron microscopic analysis. Prostate 2001; 49: 172-184.
10. Sinha AA, Quast BJ, Wilson MJ, et al: Ratio of cathepsin B to stefin A identifies heterogeneity within Gleason histologic scores for human prostate cancer. Prostate 2001; 48: 274-284.
11. Sinha AA, Morgan JL, Betre K, et al: Cathepsin B expression in prostate cancer of native Japanese and Japanese-American patients: an immunohistochemical study. Anticancer Res 2008; 28: 2271-2277.
12. Eijan AM, Sandes EO, Riveros MD, et al: High expression of cathepsin B in transitional bladder carcinoma correlates with tumor invasion. Cancer 2003; 98: 262-268.
13. Frohlich E, Schlagenhauff B, Mohrle M, et al: Activity, expression, and transcription rate of the cathepsins B, D, H, and L in cutaneous malignant melanoma. Cancer 2001; 91: 972-982. (Pubitemid 32198610)
14. Levicar N, Nuttall RK, Lah TT: Proteases in brain tumour progression. Acta Neurochir (Wien) 2003; 145: 825-838.
15. Scorilas A, Fotiou S, Tsiambas E, et al: Determination of cathepsin B expression may offer additional prognostic information for ovarian cancer patients. Biol Chem 2002; 383: 1297-1303. (Pubitemid 35215081)
16. Cao L, Taggart RT, Berquin IM, et al: Human gastric adenocarcinoma cathepsin B: isolation and sequencing of full-length cDNAs and polymorphisms of the gene. Gene 1994; 139: 163-169. (Pubitemid 24078717)
17. Epstein JI: Pathology of prostatic neoplasia. In: Campbell-Walsh Urology, 9th edn (Wein AJ, Kavoussi LR, Novick AC, et al, eds). Philadelphia: Saunders, 2007; pp 2874 - 2880.
18. Hawkins JR: Finding Mutations: the Basics. New York: Oxford University Press, 1997.
19. SM Service for SNP Assays - Protocol. Foster City: Applied Biosystems 2003; pp 3-21 - 3-25 (available at http: / /www. icmb.utexas.edu/core/DNA/ Informat ion-Sheet s /Real - t ime%20PCR/ 7900ABDsnp.pdf).
20. Salanti G, Amountza G, Ntzani EE, et al: Hardy-Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations and power. Eur J Hum Genet 2005; 13: 840-848. (Pubitemid 40946083)
21. Troyer DA, Mibiru J, Leach RJ, et al: Promise and challenge: markers of prostate cancer detection, diagnosis and prognosis. Dis Markers 2004; 20: 117-128. (Pubitemid 39149920)
22. Hsieh CL, Oakley-Girvan I, Balise RR, et al: A genome screen of families with multiple cases of prostate cancer: evidence of genetic heterogeneity. Am J Hum Genet 2001; 69: 148-158. (Pubitemid 32614027)
23. Gong G, Oakley-Girvan I, Wu AH, et al: Segregation analysis of prostate cancer in 1,719 white, African-American and Asian-American families in the United States and Canada. Cancer Causes Control 2002; 13: 471-482. (Pubitemid 34666603)
24. Lieberman R, Nelson WG, Sakr WA, et al: Executive Summary of the National Cancer Institute Workshop: highlights and recommendations. Urology 2001; 57: 4-27. (Pubitemid 32532381)
25. Nelson WG, Wilding G: Prostate cancer prevention agent development: criteria and pipeline for candidate chemoprevention agents. Urology 2001; 57: 56-63. (Pubitemid 32532387)
26. Ross RK: The role of molecular genetics in chemoprevention studies of prostate cancer. IARC Sci Publ 2001; 154: 207-213.
27. Colella R, Casey SF: Decreased activity of cathepsins L + B and decreased invasive ability of PC3 prostate cancer cells. Biotech Histochem 2003; 78: 101-108. (Pubitemid 37098617)
28. Podgorski I, Sloane BF: Cathepsin B and its role(s) in cancer progression. Biochem Soc Symp 2003; 70: 263-276. (Pubitemid 38497232)
29. Verhage BA, van Houwelingen K, Ruijter TE, et al: Single-nucleotide polymorphism in the Ecadherin gene promoter modifies the risk of prostate cancer. Int J Cancer 2002; 100: 683-685. (Pubitemid 34832978)
30. Paiss T, Herkommer K, Bock B, et al: Association between the clinical presentation and epidemiological features of familial prostate cancer in patients selected for radical prostatectomy. Eur Urol 2003; 43: 615-621. (Pubitemid 36648600)
31. Unger F: Health is wealth - toward a European lead market in health care. Acta Medico-Biotechnica 2008; 1: 11-18.